Companies › Zhejiang Yangli Pharmaceutical Technology
2 active drug programs in 2 registered trials: 2 Phase 1; Cardiovascular, Oncology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VB15010 PARP1 inhibitor | PARP1 | Phase 1 | Cancer | – |
| VB19055 | – | Phase 1 | Hypertension | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06819215 | VB15010 | Phase 1 | Cancer | Oncology | Dec 2025 |
| NCT07254481 | VB19055 | Phase 1 | Hypertension | Cardiovascular | Jul 2026 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.